Intraoperative molecular imaging used to illuminate and target non-small-cell lung cancer shows improved outcomes for 26% of patients in multi-institutional Phase 2 clinical trial.
WEST LAFAYETTE, Ind.
Percutaneous cryoblation ablation may be a reasonable treatment option for patients with clinical stage T1a papillary on renal cell carcinoma (pRCC) and clear-cell RCC (ccRCC), especially for patients with (pRCC).
Cryoablation offers an alternative for patients with cancer pain that cannot be controlled with medication. The authors of the current study undertook a review of the evidence surrounding cryoablation for pain control.